
Diagnosed 2003−2007 w/ five−year follow−up
N = 11726
Primary treatment: RP (±RT)
N = 6717 / 11726 (57%)
Very low risk 1122 / 6717 (17%)
Low risk 2781 / 6717 (41%)
Interm. risk 2814 / 6717 (42%)
Primary treatment: RT (±HT)
N = 2131 / 11726 (18%)
Very low risk 307 / 2131 (14%)
Low risk 698 / 2131 (33%)
Interm. risk 1126 / 2131 (53%)
Initial management: AS
N = 1729 / 11726 (15%)
Very low risk 644 / 1729 (37%)
Low risk 757 / 1729 (44%)
Interm. risk 328 / 1729 (19%)
Initial management: WW
N = 578 / 11726 (5%)
Very low risk 104 / 578 (18%)
Low risk 265 / 578 (46%)
Interm. risk 209 / 578 (36%)
Primary treatment: HT
N = 190 / 11726 (2%)
Very low risk 16 / 190 (8%)
Low risk 33 / 190 (17%)
Interm. risk 141 / 190 (74%)
Other primary treatment
N = 241 / 11726 (2%)
Conversion to active treatment
N = 614 / 1729 (36%)
RP 420 / 614 (68%)
RT 194 / 614 (32%)